Welcome to LookChem.com Sign In|Join Free
  • or
(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one, commonly known as chalcone, is a chemical compound characterized by a chalcone core with methoxy and hydroxyl groups attached to the phenyl rings. (E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is recognized for its diverse biological activities, such as antioxidant, anti-inflammatory, and anticancer properties. Its unique structure and chemical properties make it a promising candidate for pharmaceutical research and development.

215168-57-3

Post Buying Request

215168-57-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

215168-57-3 Usage

Uses

Used in Pharmaceutical Industry:
(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is used as a key compound for the development of new drugs targeting various health conditions. Its antioxidant, anti-inflammatory, and anticancer properties make it a valuable asset in the creation of novel therapeutic agents.
Used in Antioxidant Applications:
In the field of health and wellness, (E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is used as an antioxidant agent to combat oxidative stress and protect cells from damage. Its antioxidant properties contribute to the prevention of various diseases and the promotion of overall health.
Used in Anti-inflammatory Applications:
(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is utilized as an anti-inflammatory agent to reduce inflammation and alleviate pain associated with various conditions. Its ability to modulate inflammatory responses makes it a potential candidate for the treatment of chronic inflammatory diseases.
Used in Anticancer Applications:
Within the oncology sector, (E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is employed as an anticancer agent. Its potential to target and inhibit the growth of cancer cells makes it a promising compound for the development of new cancer therapies.
Used in Drug Delivery Systems:
(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one is also used in the development of drug delivery systems to enhance the bioavailability and therapeutic outcomes of various medications. Its structural properties allow for the creation of novel carriers and formulations that can improve the efficacy of existing drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 215168-57-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,5,1,6 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 215168-57:
(8*2)+(7*1)+(6*5)+(5*1)+(4*6)+(3*8)+(2*5)+(1*7)=123
123 % 10 = 3
So 215168-57-3 is a valid CAS Registry Number.

215168-57-3Relevant academic research and scientific papers

Natural scaffolds-inspired synthesis of CF3-substituted macrolides enabled by Rh-catalyzed C–H alkylation macrocyclization

Bi, Tongyu,Li, Jia,Lin, Zhenyang,Tang, Bixi,Xu, Xin,Xu, Yi,Yang, Qing,Yang, Weibo,Zang, Yi

, (2021/11/17)

The development of innovative strategies and methods to provide natural product-like macrocycles not accessible by biosynthesis, but endowed with novel bioactivities and simplified structure, is highly desirable. Inspired by the key scaffolds of rapamycin

NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF

-

Paragraph 00319, (2021/04/10)

The present disclosure provides neuroprotective compounds along with their use in treating disease such as Parkinson's disease (PD). The compounds can be used as inhibitors for Parthanatos Associated AIF (apoptosis-inducing factor) Nuclease (PAAN), also known as macrophage migration inhibitor factor (MIF).

PROTEIN-BINDING COMPOUNDS

-

Paragraph 0521; 0524-0526, (2020/05/19)

The technology relates in part to compounds that bind to proteins. In certain examples, the compounds can bind to proteins that bind to rapamycin. In some examples, the compounds can bind to cellular proteins, and/or variant forms of cellular proteins, th

Synthetic process of homodimer of FKBP ligand

-

Paragraph 0030; 0033; 0034, (2019/05/28)

The invention discloses a synthesis process of homodimer of FKBP ligand and belongs to an improved synthesis process of AP1903, wherein the homodimer of FKBP ligand refers to AP1903. According to theoptimized route of the synthesis process chooses, (S)-piperidine-2-methyl formate is connected to the compound Cpd9' as selected, an acid Cpd6' obtained after ester hydrolysis is easier to be purified by post-treatment purification, and precipitation or extraction treatment can be chosen by the post-treatment purification. Although the total reaction steps of the synthetic route in the prior literature are the same as the optimized route of the invention, the synthetic route in the prior literature belongs to the vertical route, and the post-treatment of the fifth, sixth and eighth steps requires column chromatography, thereby leading to a higher research and development cost. The optimized AP1903 synthetic route belongs to the parallel route, and the post-treatment is simpler and more advantageous for separation and purification, so that the cost of research and development is relatively low and the economic benefit is obviously superior to that of the synthetic route in the prior art.

MULTIMERIC PIPERIDINE DERIVATIVES

-

Page/Page column 131-133, (2019/07/13)

The technology relates in part to compounds that bind to multimeric ligand binding regions, referred to herein as "multimeric compounds." In certain examples, the multimeric compounds provided herein bind to and multimerize polypeptides that bind to rimiducid, such as for example, chimeric polypeptides that comprise FKBP12 polypeptide variant regions. Multimeric compounds provided include those having a structure of Formula I. Where A, Z, Y, Z' and A' moieties are described herein.

Synthesis and pharmacological evaluation of some novel 2-pyrazolines bearing benzenesulfonamide as anti-inflammatory and blood glucose lowering agents

Ovais, Syed,Bashir, Rafia,Yaseen, Shafiya,Rathore, Pooja,Samim, Mohammed,Javed, Kalim

, p. 1378 - 1385 (2013/04/10)

A series of novel pyrazolines (2a-l) bearing benzenesulfonamide moiety were synthesized by condensing appropriate chalcone (1a-l) with 4- hydrazinobenzenesulfonamide hydrochloride. Structure of all novel synthesized compounds was characterized on basis of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 215168-57-3